Informatie: Dit is niet de actueelste versie van het datamodel. Een versieoverzicht vindt u links onder Versies. De actueelste versie vindt u hier.
Informatie:
Fout:
ID
15369
Beschrijving
Effect of Liraglutide on the Beta-cell Responsiveness in Subjects With Type 2 Diabetes Compared to a Healthy Control Group; ODM derived from: https://clinicaltrials.gov/show/NCT01511185
Link
https://clinicaltrials.gov/show/NCT01511185
Trefwoorden
Versies (2)
- 28-05-16 28-05-16 -
- 20-09-21 20-09-21 -
Geüploaded op
28 mei 2016
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Diabetes NCT01511185
Eligibility Diabetes NCT01511185
- StudyEvent: Eligibility
Similar models
Eligibility Diabetes NCT01511185
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
type 2 diabetes
Item
diagnosed with type 2 diabetes, either newly diagnosed with at least 2 months of diet or on oad monotherapy for at least 3 months
boolean
C0011860 (UMLS CUI [1,1])
C2585997 (UMLS CUI [1,2])
C0011860 (UMLS CUI [2,1])
C0935929 (UMLS CUI [2,2])
C0442027 (UMLS CUI [2,3])
C2585997 (UMLS CUI [1,2])
C0011860 (UMLS CUI [2,1])
C0935929 (UMLS CUI [2,2])
C0442027 (UMLS CUI [2,3])
bmi
Item
body mass index (bmi): 24-35 kg/m^2 inclusive
boolean
C1305855 (UMLS CUI [1])
type 2 diabetes
Item
subjects with type 2 diabetes
boolean
C0011860 (UMLS CUI [1])
investigational drug
Item
receipt of any investigational drug within three months prior to this trial
boolean
C0013230 (UMLS CUI [1])
hypoglycemia
Item
recurrent severe hypoglycemia as judged by the investigator
boolean
C0020615 (UMLS CUI [1])
cardiac disease
Item
cardiac disease
boolean
C0018799 (UMLS CUI [1])
drug affecting glucose level
Item
use of any drug (except an oad (oral anti-diabetic drug)) that in the investigator's opinion could interfere with the blood glucose level
boolean
C0013227 (UMLS CUI [1,1])
C0202042 (UMLS CUI [1,2])
C0202042 (UMLS CUI [1,2])
haemoglobin
Item
haemoglobin maximum 10 g/l
boolean
C0518015 (UMLS CUI [1])
hba1c
Item
hba1c above 12%
boolean
C0019018 (UMLS CUI [1])
bleeding
Item
loss of more than 400 ml blood during the 3 months prior to trial start
boolean
C0019080 (UMLS CUI [1])
healthy subject
Item
healthy subjects
boolean
C1708335 (UMLS CUI [1])
cardiac disease | ecg abnormality
Item
clinically relevant cardiac disease or any clinically significant abnormal ecg (electrocardiogram)
boolean
C0018799 (UMLS CUI [1])
C1832603 (UMLS CUI [2])
C1832603 (UMLS CUI [2])
hba1c
Item
hba1c at least 6%
boolean
C0019018 (UMLS CUI [1])